Streetwise Biotechnology / Pharmaceuticals Articles
PDUFA Date Coming Up for U.K. Biopharma
Source: Edward Nash (4/22/24)
The company has a commercialization plan in place and is preparing further for approval, noted a Canaccord Genuity report.
More >
Biopharma's New Drug for COPD Likely to be Approved
Source: Ram Selvaraju (4/22/24)
Characteristics of the Buy-rated company's lead candidate make it "an intriguing commercial prospect," noted an H.C. Wainwright & Co. report.
More >
Analyst Says Pharma Co. Has No True Competitor
Source: Andrew Tsai (4/19/24)
Verona Pharma Plc. recently is gearing up for a potential FDA approval of its twice-daily ensifentrine, according to a Jefferies & Co. research note.
More >
LA Biotech's Lower Revenue Will Be Short Lived
Source: Dr. Jonathan Aschoff (4/17/24)
While Ontrak Inc. may have had a loss in revenue in 2023, this will be short-lived, according to a Roth MKM research note.
More >
Chen in Q2 2024: It's Silver, Again, as Precious Metal Breaks Out
Source: Streetwise Reports (4/8/24)
After being bullish on silver for at least the last year, asset manager Chen Lin feels a little vindicated by the precious metal's recent two-year high.
More >
Biotech's Lawsuit With Eli Lilly Might Catalyze Stock
Source: Streetwise Reports (3/27/24)
Nektar Therapeutics has commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin in patients with severe to very severe alopecia areata. In other news, Nektar has a lawsuit pending against Eli Lilly & Co. Read on to see what two experts have to say about this biotech stock.
More >
Biotech Co.'s Target Price Significantly Higher Than Current
Source: Dr. Jonathan Aschoff (3/19/24)
Biofrontera Inc. is currently trading at US$1.26, but has a target price of US$26, according to a Roth MKM research note.
More >
Biotech Stocks Break Out
Source: Ron Struthers (3/19/24)
Ron Struthers of Struthers Stock Report shares that the S&P Biotech SPDR is over 60% this year and trading around $100 a share. He also details how well he has down, buying under valued cash-rich biotechs in 2023, and shares one stock he believes it worth looking into.
More >
Is This Pharma Set To Break Out After COPD Drug Approval?
Source: Streetwise Reports (3/15/24)
Clinical-stage biopharmaceutical company Verona Pharma Plc is looking toward a pivotal year as its new chronic obstructive pulmonary disease (COPD) drug ensifentrine nears possible approval by the FDA. At least two research companies have named it a top pick for 2024.
More >
This Biotech Is a Potential Disruptor, Expert Says
Source: Chris Temple (3/12/24)
Chris Temple of The National Investor shares why he believes BetterLife Pharma Inc. is an Immediate Buy.
More >
NY Biotech Has Potentially Game Changing Anxiety Therapy
Source: Dr. Jonathan Aschoff (3/7/24)
Mind Medicine (MindMed) Inc. recently announced positive results from its Phase 2b trial of MM120 in generalized anxiety disorder, according to a Roth MKM research note.
More >
Alt-Pharma VC adds 7% Stake in Testing Strip Firm
Source: Streetwise Reports (2/15/24)
Alt pharma is hot these days, and few companies are coming in hotter than Safe Supply Streaming Co. Ltd., which just secured a 7% stake in a leading medical test company to expand its functional portfolio.
More >
Cash Rich Biotech Could Win a Lawsuit With Lilly, Expert Says
Source: Ron Struthers (2/12/24)
Ron Struthers explains how the cash value of this biotech is about $1.68/share and the stock is selling at around -58% discount to cash value. He also discusses a recent lawsuit with Eli Lilly.
More >
Drug Reformer Subsidiary Inspected for Dealer License
Source: Streetwise Reports (2/2/24)
In a "transformative moment" for the company, a Safe Supply Streaming Co. Ltd. subsidiary has undergone an official inspection by Health Canada to acquire a dealer license to produce, distribute, and export controlled substances.
More >
Leadership Cuts Won't Slow This Biotech
Source: Robert Burns (1/26/24)
While three executive officers have been cut from Kronos Bio Inc., it is still a Buy, according to an H.C. Wainwright & Co. report.
More >
Pharma Co. Primed for Future Business
Source: Dr. Andre Uddin (1/25/24)
Analysts at Research Capital believe that Knight Therapeutics Inc. is primed to conduct future business development.
More >
Healthcare Co. Exceeds Expectations in Performance
Source: Dr. Yi Chen (1/24/24)
Sensus Healthcare Inc. released fourth-quarter financials that surpassed expectations, according to an H.C. Wainwright & Co. research note.
More >
Money Manager: The Year of Small Caps?
Source: Streetwise Reports (1/16/24)
The president and chief executive officer of Toronto-based AlphaNorth Asset Management says his positive outlook on 2024 has not changed. In fact, it could be a great year for small caps.
More >
Big Pharma's Looming Patents May Benefit One Biotech
Source: Streetwise Reports (1/10/24)
Pharma stocks took big hits in recent years as many of its largest companies saw a looming "patent cliff" that could dry out profits from their big cash-cow drugs. This may be good for smaller pharma companies like one stock, which was one of Chen Lin's top picks for 2024.
More >
Biotech Co.'s Sales Could Grow To US$310 Million in 2028
Source: Edward White (1/10/24)
Biotech Valneva SE announced that it had dosed the first participant in a Phase 2 pediatric trial evaluating its chikungunya vaccine candidate, according to an H.C. Wainwright & Co. report.
More >
2024: Chen Leads With Biotech After Picking 2023's Top Stock
Source: Streetwise Reports (1/5/24)
Asset manager Chen Lin was very happy with his picks from 2023, including one that ended up soaring 1,900%. See what the asset manager has lined up for the new year.
More >
Market Correction and One Cash Rich Biotech
Source: Ron Struthers (1/3/24)
In late December, Ron Struthers pointed out that the S&P 500 made a double top and showed numerous over-bought conditions, so a correction is expected. He also shared one biotech that has been whacked down way below its cash value.
More >
Boston Biotech Could Have Blockbuster Sales
Source: Robert Burns (1/3/24)
Tango Therapeutics may have "blockbuster potential," noted an H.C. Wainwright & Co. report.
More >
Pharma Co. Gets First US Patent for Repurposed Drug
Source: Streetwise Reports (1/2/24)
Clinical-stage pharmaceuticals firm Algernon Pharmaceuticals Inc. has been issued a U.S. patent for the treatment of three related diseases with its investigational drug repirinast.
More >
California-Based Pharma Co.'s Progress Offers Upside
Source: Dr. Swayampakula Ramakanth (1/2/24)
While H.C. Wainwright & Co. lowered their price target, they still see upside for this pharmaceutical company.
More >